“Chronic Kidney Disease (CKD) Pipeline Analysis” gives comprehensive
insight on the various drugs being developed for the treatment of CKD. The
report covers all the drugs being developed in various phases (Discovery,
Preclinical, Clinical & Marketing). The pipeline focuses on novel
pharmacologic drugs & regenerative medicines covering small molecules,
monoclonal antibodies, stem cell therapies and RNA-based therapeutics, but
excludes symptom relief drugs. The report also covers some of the hot targets
in research for CKD treatments.
This report enables Pharmaceutical /Biotech companies, Academic
institutes, Individual researchers, Investors, Medical technology companies,
Service providers and other associated stake holders to identify and analyze
the available licensing/collaborative commercial opportunities in the CKD Drug
market. The report also provide strategic insights on medicines that are likely
to have an impact on CKD treatment space and potentially alter standards of
care in CKD in the foreseeable future.
Current therapies are not effective and more than half of patients
gradually face severe renal and cardiovascular complications, hence it provides
a tremendous opportunity for upcoming therapies specific to CKD such as MAbs,
stem cell-based and RNA-based therapies, which reverses disease course or slow
down kidney deterioration.
Spanning over 112 pages, “Chronic
Kidney Disease - Pipeline Analysis” report covers Report
Description, Introduction, Hot Targets, Mechanisms And Therapies, Market Data,
Pipeline Analysis, Small Molecules, Large Molecules, Monoclonal Antibodies,
Stem Cell Therapy, RNA Based Therapeutics, Major Players, References. The
report covered companies are - Angion Biomedica, Astellas Pharma, Astrazeneca,
Blr Bio, Eli Lilly & Co, Opko Health Inc, Pfizer, Regulus Therapeutics,
Johnson & Johnson, Vidasyam Inc
For
further information on this report, please visit- http://mrr.cm/4mz
Find
all Therapeutic Reports at: http://www.marketresearchreports.com/therapeutic
No comments:
Post a Comment
Note: only a member of this blog may post a comment.